Authors : Kwan JM; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America.; Yale University School of Medicine, New Haven, Connecticut, United States of America.

Subjects: Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/adverse effects ; Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/Immune Checkpoint Inhibitors*/therapeutic use ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/diagnostic imaging

Source: PloS one [PLoS One] 2024 Dec 02; Vol. 19 (12), pp. e0314555. Date of Electronic Publication: 2024 Dec 02 (Print Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.

Authors : Cui, Ran¹ (AUTHOR); Li, Yun¹ (AUTHOR); Yu, Xinlin² (AUTHOR)

Subjects: *NON-small-cell lung carcinoma; *IMMUNE checkpoint inhibitors; *PROGRESSION-free survival

Source: PLoS ONE. 6/12/2024, Vol. 19 Issue 6, p1-21. 21p.

Record details

Read Online Read More Add to Saved list

Academic Journal

The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.

Authors : Kang, Jing^1,2,3 (AUTHOR); Zhang, Jun³ (AUTHOR); Tian, Zongsheng¹ (AUTHOR)

Subjects: *NON-small-cell lung carcinoma; *PROGRESSION-free survival; *IMMUNE checkpoint inhibitors

Source: PLoS ONE. 2/6/2024, Vol. 19 Issue 2, p1-13. 13p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Authors : Tan, Zhongbao¹ (AUTHOR); Zhang, Jian¹ (AUTHOR); Xu, Lan² (AUTHOR)

Subjects: *SORAFENIB; *IMMUNE checkpoint inhibitors; *PROTEIN-tyrosine kinase inhibitors

Source: PLoS ONE. 10/16/2023, Vol. 18 Issue 10, p1-13. 13p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.

Authors : Liu, Tingting^1,2 (AUTHOR); Wu, Sijia^3,4 (AUTHOR); Fang, Weiwei² (AUTHOR)

Subjects: *IMMUNE checkpoint inhibitors; *IMMUNOCOMPUTERS; *NON-small-cell lung carcinoma

Source: PLoS ONE. 4/18/2023, Vol. 18 Issue 4, p1-24. 24p.

Record details

Read Online Read More Add to Saved list

Academic Journal

MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.

Authors : Barbeau, Lydie M. O.¹ (AUTHOR); Beelen, Nicky A.^2,3 (AUTHOR); Savelkouls, Kim G.¹ (AUTHOR)

Subjects: *NON-small-cell lung carcinoma; *IMMUNE checkpoint inhibitors; *SQUAMOUS cell carcinoma

Source: PLoS ONE. 2/10/2025, Vol. 20 Issue 2, p1-19. 19p.

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Effect of immortal time bias on the association between immune-related adverse events and oncological outcomes following immune checkpoint inhibitors therapy for head and neck squamous cell carcinoma.

Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.

Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors.

Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors.

Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.

The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.

Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.

MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.

Contact

Follow us